See the DrugPatentWatch profile for Alemtuzumab
What does “alemtuzumab LOE date” usually mean?
“LOE” in drug tracking most commonly means “loss of exclusivity” (the point when a brand’s market protection ends, allowing generic or biosimilar competition). For alemtuzumab, the exact LOE date depends on the specific product name, country, and whether the protection you’re tracking is primary patent expiry, supplementary protection certificates (SPCs), data/market exclusivity rules, or court/settlement outcomes. The provided information here does not include any specific LOE date.
Which alemtuzumab product do you mean?
“Alemtuzumab” is the active ingredient used in different medicines (for example, branded products in specific regions). LOE dates are product- and jurisdiction-specific, so you need at least:
- The brand/product (and strength/form)
- The country (e.g., US, UK, EU, etc.)
- The LOE definition you want (patent expiry vs. data exclusivity vs. biosimilar entry)
How is the LOE date determined for biologics like alemtuzumab?
For antibody drugs, “loss of exclusivity” often reflects a mix of legal protections, such as patents covering formulation/use and any regulatory exclusivity that delays approval or launch of competing products. Litigation or patent challenges can also shift timing.
If you tell me your region/product, can you give the LOE date?
Yes. Share:
1) the country/market,
2) the exact alemtuzumab brand you’re tracking, and
3) whether you mean “first generic/biosimilar launch” or “end of protection (no barriers to approval/marketing).”
Then I can help pinpoint the relevant LOE date using the correct protections for that setting.
Sources
No sources were provided with your question, so I can’t cite an LOE date accurately yet.